792 related articles for article (PubMed ID: 10946864)
1. Effects of testosterone replacement in hypogonadal men.
Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
[TBL] [Abstract][Full Text] [Related]
2. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
[TBL] [Abstract][Full Text] [Related]
3. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
4. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
6. Effect of testosterone treatment on bone mineral density in men over 65 years of age.
Snyder PJ; Peachey H; Hannoush P; Berlin JA; Loh L; Holmes JH; Dlewati A; Staley J; Santanna J; Kapoor SC; Attie MF; Haddad JG; Strom BL
J Clin Endocrinol Metab; 1999 Jun; 84(6):1966-72. PubMed ID: 10372695
[TBL] [Abstract][Full Text] [Related]
7. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
Behre HM; Kliesch S; Leifke E; Link TM; Nieschlag E
J Clin Endocrinol Metab; 1997 Aug; 82(8):2386-90. PubMed ID: 9253305
[TBL] [Abstract][Full Text] [Related]
9. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
10. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
[TBL] [Abstract][Full Text] [Related]
11. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone replacement on trabecular architecture in hypogonadal men.
Benito M; Vasilic B; Wehrli FW; Bunker B; Wald M; Gomberg B; Wright AC; Zemel B; Cucchiara A; Snyder PJ
J Bone Miner Res; 2005 Oct; 20(10):1785-91. PubMed ID: 16160736
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
[TBL] [Abstract][Full Text] [Related]
15. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception.
Young NR; Baker HW; Liu G; Seeman E
J Clin Endocrinol Metab; 1993 Oct; 77(4):1028-32. PubMed ID: 8408450
[TBL] [Abstract][Full Text] [Related]
16. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.
Dabaja AA; Bryson CF; Schlegel PN; Paduch DA
BJU Int; 2015 Mar; 115(3):480-5. PubMed ID: 25046796
[TBL] [Abstract][Full Text] [Related]
17. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
Swerdloff RS; Wang C
Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
Zacharin MR; Pua J; Kanumakala S
Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
[TBL] [Abstract][Full Text] [Related]
19. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome.
Rodriguez-Tolrà J; Torremadé J; di Gregorio S; Del Rio L; Franco E
Andrology; 2013 Jul; 1(4):570-5. PubMed ID: 23686863
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
